Mpox Antiviral & Vaccine Pipeline — PatSnap Eureka
Mpox Antiviral & Vaccine Pipeline: Tecovirimat Combinations and Next-Generation Orthopoxvirus Approaches
From tecovirimat's VP37 mechanism to mRNA vaccine candidates and novel small-molecule combinations, the mpox therapeutic landscape is evolving rapidly. PatSnap Eureka maps the full pipeline so R&D teams can identify white spaces, track competitors, and prioritise the most promising orthopoxvirus programmes.
The Mpox Therapeutic Landscape: From Approved Agents to Emerging Candidates
The mpox drug pipeline centres on a small set of approved or emergency-authorised agents — tecovirimat (TPOXX), brincidofovir, and cidofovir — alongside the WHO-endorsed JYNNEOS (MVA-BN) vaccine from Bavarian Nordic. Each addresses a distinct point in the orthopoxvirus replication cycle, from viral egress to DNA synthesis. The PatSnap life sciences intelligence platform tracks all active programmes across patent filings, clinical registries, and regulatory submissions globally.
Tecovirimat's mechanism — inhibiting the VP37 envelope protein to block viral egress — makes it the cornerstone of current treatment protocols. However, emerging resistance signals in immunocompromised patients have accelerated interest in combination regimens and mechanistically distinct alternatives. The NIH's NIAID has funded multiple combination studies to address this gap. Researchers are also exploring the D13 scaffold protein, the I7L protease, and viral DNA polymerase (E9L) as next-generation targets, broadening the orthopoxvirus antiviral toolkit beyond a single mechanism class.
On the vaccine side, ACAM2000 (a replication-competent vaccinia vaccine stockpiled by Emergent BioSolutions) and JYNNEOS represent the current standard. Next-generation candidates include mRNA platforms, subunit vaccines targeting orthopoxvirus surface antigens such as A33 and B5, and novel adjuvanted formulations designed to broaden cross-clade protection. The PatSnap Analytics platform enables teams to map these emerging technologies against existing IP landscapes in real time.
Combination Strategies to Address Resistance and Improve Efficacy
As resistance signals emerge in immunocompromised patients, researchers are pursuing multi-target combination regimens that attack orthopoxvirus replication at multiple stages simultaneously.
Tecovirimat + Brincidofovir
This combination pairs VP37 egress inhibition (tecovirimat) with brincidofovir's lipid-conjugate mechanism that delivers cidofovir intracellularly to inhibit viral DNA polymerase (E9L). The dual-target approach reduces the probability of resistance emergence by requiring simultaneous mutations at two distinct loci. Early in vitro data support additive to synergistic activity against orthopoxviruses including vaccinia and monkeypox virus (MPXV).
Dual-target: VP37 + E9L polymeraseTecovirimat + Cidofovir
Cidofovir, a broad-spectrum nucleotide analogue, inhibits viral DNA synthesis and has established activity against orthopoxviruses. When combined with tecovirimat, the pairing addresses both replication and egress. Nephrotoxicity remains a limiting factor for cidofovir, driving interest in the brincidofovir prodrug approach; however, cidofovir combinations remain relevant in settings where brincidofovir is unavailable or in patients with specific tolerability profiles.
Replication + egress blockadeTecovirimat + NIOCH-14
NIOCH-14 is a Russian-developed antiviral with a distinct mechanism targeting early stages of orthopoxvirus replication, proposed to act on viral entry or early gene expression. Preclinical data from Russian institutions have demonstrated activity against MPXV. The combination with tecovirimat is being explored to provide coverage across both early replication and late egress phases, potentially relevant for high-risk or treatment-refractory cases.
Early replication + egressTecovirimat + Immunomodulators
In immunocompromised patients — the population at highest risk for severe mpox and tecovirimat resistance — combining antiviral therapy with immunomodulatory agents such as vaccinia immune globulin intravenous (VIGIV) or investigational immune checkpoint approaches is under evaluation. VIGIV provides passive immunity while tecovirimat suppresses viral spread, offering a complementary mechanism in patients whose immune systems cannot mount adequate responses to vaccination or infection alone.
Antiviral + passive immunityOrthopoxvirus Programme Distribution Across Development Stages
Patent and clinical registry data reveal where the pipeline is concentrated and where the largest gaps in late-stage development remain.
Active Programmes by Development Stage
The pipeline is heavily preclinical — 48 programmes — with a significant drop-off at Phase III, signalling a late-stage gap in the orthopoxvirus antiviral and vaccine space.
Pipeline Share by Mechanism Class
VP37 egress inhibitors dominate at 34% of the pipeline, but DNA polymerase inhibitors and next-generation vaccine platforms collectively account for nearly half of all active programmes.
Beyond Tecovirimat: Novel Targets and Vaccine Platforms
Researchers are pursuing mechanistically distinct antivirals and advanced vaccine platforms to address resistance, broaden coverage, and improve access in endemic regions.
D13 Scaffold Protein Inhibitors
The D13 scaffold protein is essential for immature virion assembly in orthopoxviruses. Small molecules targeting D13 represent a structurally distinct mechanism from VP37 inhibition, offering a resistance-independent alternative. Rifampicin has historically been used as a D13 inhibitor in research settings, and novel analogues with improved selectivity are in preclinical development.
I7L Protease Inhibitors
The I7L cysteine protease is required for orthopoxvirus core protein maturation. Inhibiting I7L blocks the production of infectious virions at a late stage of the replication cycle, complementary to both egress inhibitors and DNA polymerase inhibitors. Structure-based drug design efforts targeting the I7L active site are ongoing at several academic centres.
Leading Organisations in the Mpox Pipeline
From biotech innovators to government-funded programmes, these organisations are shaping the mpox therapeutic and vaccine landscape.
| Organisation | Lead Asset | Mechanism / Target | Stage | Focus Area |
|---|---|---|---|---|
| SIGA Technologies | Tecovirimat (TPOXX) | VP37 egress inhibitor | Approved / EUA | Smallpox / Mpox treatment |
| Bavarian Nordic | JYNNEOS (MVA-BN) | Non-replicating MVA vaccine | Approved | Mpox / Smallpox prevention |
| Emergent BioSolutions | ACAM2000 | Replication-competent vaccinia | Approved | Strategic national stockpile |
| Chimerix | Brincidofovir (CMX001) | Lipid-conjugate DNA polymerase inhibitor | Phase III | Orthopoxvirus combination therapy |
| NIAID / BARDA | Multiple combination studies | Tecovirimat combinations; novel targets | Phase I–II | Government-funded R&D |
Track competitor pipeline moves as they happen
PatSnap Eureka monitors patent filings, clinical trial updates, and regulatory submissions across all key mpox pipeline organisations in real time.
Mpox Antiviral & Vaccine Pipeline — key questions answered
Tecovirimat (TPOXX) is a small-molecule antiviral that targets the VP37 envelope protein of orthopoxviruses, blocking viral egress and preventing cell-to-cell spread. It is currently the leading antiviral candidate for mpox treatment and has received regulatory approval in several jurisdictions for smallpox, with expanded use being studied for mpox.
Researchers are investigating tecovirimat in combination with brincidofovir, cidofovir, and NIOCH-14 to address potential resistance and improve efficacy. These combinations target multiple stages of the orthopoxvirus replication cycle, reducing the likelihood of resistance emergence.
JYNNEOS (MVA-BN) is the primary approved non-replicating modified vaccinia Ankara vaccine for mpox and smallpox prevention. ACAM2000, a replication-competent vaccinia vaccine, is also stockpiled. Next-generation candidates include mRNA-based vaccines, subunit vaccines targeting orthopoxvirus surface antigens, and novel adjuvanted formulations designed to broaden cross-protection.
Key challenges include the risk of tecovirimat resistance in immunocompromised patients, limited clinical trial data given the sporadic nature of outbreaks, manufacturing scalability for novel biologics, and ensuring equitable access in endemic regions of Central and West Africa where cold-chain infrastructure is limited.
Next-generation antivirals pursue alternative viral targets such as the D13 scaffold protein, viral DNA polymerase (E9L), and the I7L protease, offering mechanistically distinct options to tecovirimat's VP37-focused mechanism. Candidates such as brincidofovir (a lipid conjugate of cidofovir) and novel small molecules aim to provide broader orthopoxvirus coverage with improved oral bioavailability.
Key players include SIGA Technologies (tecovirimat), Bavarian Nordic (JYNNEOS/MVA-BN), Emergent BioSolutions (ACAM2000), Chimerix (brincidofovir), and multiple academic institutions and government-funded programmes such as BARDA and NIAID in the United States, alongside WHO-coordinated international efforts.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About the Mpox PipelineAccelerate Your Mpox and Orthopoxvirus R&D with AI-Powered Pipeline Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track antiviral combinations, map vaccine IP, and identify the next orthopoxvirus breakthrough.
References
- World Health Organization — Mpox Fact Sheet
- NIH / NIAID — Tecovirimat Clinical Trial for Mpox
- CDC — Mpox Treatment Guidance for Clinicians
- FDA — TPOXX (Tecovirimat) Drug Approvals and Trials
- Bavarian Nordic — JYNNEOS (MVA-BN) Vaccine Pipeline
- ClinicalTrials.gov — Active Mpox Antiviral Studies
- PatSnap — Life Sciences Innovation Intelligence Platform
All pipeline data and programme counts on this page are derived from patent and regulatory filing analysis conducted via the PatSnap innovation intelligence platform and PatSnap Eureka. Clinical stage data reflects publicly available registry and regulatory information at the time of publication.
PatSnap Eureka searches patents and research literature to answer instantly.